Drug Trial Radar · NCT02460159
A Clinical Trial to Assess the Long Term Safety and Tolerability of MK-0653C in Japanese Participants With Hypercholesterolemia (MK-0653C-384)
Last checked: Nov 19, 2026Latest source record: May 16, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
135
Actual
Start
Jun 23, 2015
Primary completion
Dec 22, 2016
Study completion Dec 22, 2016
Sponsor
- Lead sponsor
- Organon and CoIndustry
- Sponsor type
- Industry
- First posted
- Jun 2, 2015
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 20 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will assess the safety and tolerability of Ezetimibe (EZ) 10 mg/Atorvastatin (Atora) 10 mg and EZ 10mg/Atora 20 mg fixed-dose combination (FDC) in Japanese participants with hypercholesterolemia uncontrolled with monotherapy of Ezetimibe 10 mg or Atorvastatin up to 20 mg. There is no formal hypothesis for the study.
Conditions
- Hypercholesterolemia
- Heterozygous Familial Hypercholesterolemia
Interventions
EZ 10 mg/Atorva 20 mg FDCDrug
EZ 10 mg/Atorva 10 mg FDCDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants Who Experience 1 or More Adverse Event (AE)Time frame: up to 54 Weeks
- Percentage of Participants Who Experience 1 or More Gastrointestinal-related AEsTime frame: up to 54 weeks
- Percentage of Participants Who Experience 1 or More Gallbladder-related AEsTime frame: up to 54 weeks
- Percentage of Participants Who Experience 1 or More Allergic Reaction or Rash AEsTime frame: up to 54 weeks
- Percentage of Participants Who Experience 1 or More Hepatitis-related AEsTime frame: up to 54 weeks
- Percentage of Participants Who Experience Consecutive Elevations in Alanine Aminotransferase (ALT) and/or Aspartate Aminotransferase (AST) ≥3 Times Upper Normal Limit (ULN)Time frame: up to 52 weeks
- Percentage of Participants Who Experience Elevations in ALT or AST ≥5 Times ULNTime frame: up to 52 weeks
- Percentage of Participants Who Experience Elevations in ALT or AST ≥10 Times ULNTime frame: up to 52 weeks
- Percentage of Participants With Potential Hy's Law ConditionTime frame: up to 52 weeks
- Percentage of Participants Who Experience Elevations in Creatine Kinase (CK) ≥10 Times ULNTime frame: up to 52 weeks
- Percentage of Participants Who Experience Elevations in Creatine Kinase (CK) ≥10 Times ULN With Muscle SymptomsTime frame: up to 52 weeks
- Percentage of Participants Who Experience Elevations in Creatine Kinase (CK) ≥10 Times ULN and Drug-Related Muscle SymptomsTime frame: up to 52 weeks
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.